Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bicycle Therapeutics Plc ADR (BCYC)

Bicycle Therapeutics Plc ADR (BCYC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 506,946
  • Shares Outstanding, K 29,646
  • Annual Sales, $ 11,700 K
  • Annual Income, $ -66,820 K
  • 60-Month Beta 0.56
  • Price/Sales 43.97
  • Price/Cash Flow N/A
  • Price/Book 1.56
Trade BCYC with:

Options Overview Details

View History
  • Implied Volatility 148.68% ( +6.27%)
  • Historical Volatility 169.60%
  • IV Percentile 98%
  • IV Rank 65.48%
  • IV High 191.72% on 10/01/21
  • IV Low 67.05% on 08/16/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 297
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 4,568
  • Open Int (30-Day) 4,014

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.82
  • Number of Estimates 8
  • High Estimate -0.67
  • Low Estimate -1.15
  • Prior Year -0.74
  • Growth Rate Est. (year over year) -10.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.08 +13.68%
on 05/12/22
27.02 -32.35%
on 04/20/22
-5.73 (-23.87%)
since 04/14/22
3-Month
16.08 +13.68%
on 05/12/22
50.47 -63.78%
on 04/08/22
-26.66 (-59.32%)
since 02/17/22
52-Week
16.08 +13.68%
on 05/12/22
62.08 -70.55%
on 11/15/21
-12.66 (-40.92%)
since 05/17/21

Most Recent Stories

More News
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today reported...

BCYC : 18.28 (+6.90%)
Here's Why Bicycle Therapeutics Stock Looks Ill Today

Lackluster clinical trial results for its lead candidate are to blame.

BCYC : 18.28 (+6.90%)
SGEN : 146.55 (+2.81%)
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?

Bicycle Therapeutics PLC Sponsored ADR (BCYC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest...

BCYC : 18.28 (+6.90%)
CLSD : 1.5500 (+6.16%)
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 18.28 (+6.90%)
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 18.28 (+6.90%)
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 18.28 (+6.90%)
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 18.28 (+6.90%)
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?

Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

VIR : 23.09 (+3.64%)
BCYC : 18.28 (+6.90%)
Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 18.28 (+6.90%)
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 18.28 (+6.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 18.87
2nd Resistance Point 18.37
1st Resistance Point 17.74
Last Price 18.28
1st Support Level 16.61
2nd Support Level 16.11
3rd Support Level 15.48

See More

52-Week High 62.08
Fibonacci 61.8% 44.50
Fibonacci 50% 39.08
Fibonacci 38.2% 33.65
Last Price 18.28
52-Week Low 16.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar